To What Extent are We Applying Current Medical Treatment Approaches in Coronary Artery Disease?  by Samsa, Murat et al.
Table 1
Progression group
n¼40
Non-progression group
n¼40
p
value
Age, year 61.8  11.1 60.3  14.6 0.605
Sex, male 24 (%60) 28 (%70) 0.348
BMI, kg/m2 28.4  4.1 27.7  4.2 0.448
DBP, mmhg 75.6  9.1 76.5  12.3 0.718
Heart rate, beats/
min
78.2  7.5 77.1  8.9 0.561
Follow up, month 24.9  17.0 22.7  15.2 0.546
Previous DM, % 11 (%28) 16 (%40) 0.237
Previous HT, % 26 (%65) 24 (%60) 0.644
Smoking,% 18 (%45) 11 (%28) 0.104
Previous CVD, % 1 (%3) 1 (%3) 1.000
LVEF, % 56.9  8.8 53.3  10.2 0.089
Baseline characteristics of patients Data are expressed as mean  SD or median for normally
distributed data and percentage (%) for categorical variables. BMI: Body mass index, SBP:
systolic blood pressure, DBP: Diastolic blood pressure, DM: Diabetes mellitus, HT: Hyperten-
sion, CVD: Cerebro vascular disease, LVEF: Left ventricular ejection fraction
Table 2
Progression group
n¼40
Non-progression group
n¼40
p
value
Glucose, mg/dL 117.9  36.7 129.3  37.4 0.171
Creatinine, mg/dL 0.9  0.2 0.9 0.3 0.284
AST (u/L) 28.7  18.1 29.3  28.8 0.756
ALT (u/L) 27.7  22.8 29.5  18.1 0.701
Calcium, mg/dL 8.9  0.5 9.2  0.5 0.094
Magnesium, mmol/L 0.86  0.14 0.85  0.10 0.775
Total bilirubin, mg/dL 0.66  0.38 0.65  0.30 0.948
GGT, mg/dL 30.5  19.7 34.1  18.5 0.405
Total cholesterol,
mg/dL
180.4  42.6 186.1  43.1 0.554
LDL-C, mg/dL 114.1  31.5 116.7  30.1 0.697
HDL-C, mg/dL 37.9  7.2 35.5  7.3 0.141
Triglycerides, mg/dL 146.8  61.4 173.3  86.4 0.118
White blood cell,
x109/L
7.67  2.72 9.04  3.33 0.046
Hemoglobin, g/L 14.2  1.6 14.0  1.7 0.649
Neutrophil, 103/mL 5.31  2.67 6.25  3.08 0.149
Lymphocyte, 103/mL 1.62  0.71 1.99  0.78 0.032
Hs-CRP, mg/L 5.26  3.45 6.70  4.42 0.245
Laboratory parameters of patients Data are expressed as mean  SD or median for normally
distributed data. AST: Aspartate amino transferase ALT: Alanine amino transferase, GGT:
Gamma glutamyl transferase, LDL-C: Low density lipoprotein cholesterol, HDL-C: High density
lipoprotein cholesterol, Hs-CRP: High sensitivity C-reactive protein.
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Introduction and Aim: Coronary artery disease (CAD) is the most frequently seen
form of heart diseases. Globally, it is the leading cause of mortality in both gender. In
recent years, there have been new improvements in the medical treatment of CAD. In
most of the patients medical therapy is found to be more effective than revascularization
therapies. In order to increase the success of treatments, therapies should be applied in
accordancewith the guidelines and the objectives in these guidelines should be achieved.
In this study, we evaluated the patients, with angiographically documented coronary
artery diseasewhowere followed in our outpatient clinic and applied for the drug therapy
re-arrangement after thewithdrawal ofmedium acting nitrates. The aim of this study is to
evaluate the treatments used and drug efﬁcacy in these patients.
Methods: 72 patients (42 male, 30 female; age 6718 years) were evaluated in this
study. These patients were diagnosed CAD with coronary angiography and were fol-
lowed in our outpatient clinic. After the withdrawal of medium acting nitrates these
patients were examined again in the secondary care cardiology ouypatient clinic for drug
therapy rearrangement. Patients were divided into three groups; 22 patients (30,6%)
were using medical therapy, 20 patients (27,8%) had Percutaneous Coronary Inter-
vention (PCI), 30 patients (41,7%) had coronary artery bypass graft (CABG) operation.
Patients’ clinical, demographic proﬁle and medical treatments were recorded.
Fındıngs: : 19 patients (26,4%) were diabetic, 59 were (81,9%) hypertensive and 29
were (35,3%) smokers. 49 patients (68,1%) were using angiotensin converting
enzyme inhibitors (ACE inh.), 57 were (79,2%) using beta blockers (B blk.), 26 were
(36,1%) using statins, 70 were (97,2%) using acetylsalicylic acid (ASA) and 20 were
(27,8%) using calcium channel blockers (CCB). We have found statistically signiﬁ-
cant difference between three groups in use of ACE inhibitors (p¼0.018). When we
analyzed, we found that this statistically signiﬁcant difference was caused by the lesser
usage of ACE inh. in the CABG group. We also found statistically signiﬁcant
difference in statin use between three groups (p<0.001).
Results: This study showed that in our country, drugs such as ACE inhibitors, statins
and beta blockers, which are proven to have favourable effects on mortality, have been
used far less than the guidelines’ recommendations, however the patient group who
had PCI seems to do better in reaching these goals. In the hospitalization period,
which is important for patients compliance, patients and doctors should gain
consciousness about these agents and encourage the usage of these agents.
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Aım: Cardiovascular disease is themain reasonofmortality in adults. Atherogenesis and
thrombosis that often added on are the main reason of cardiovascular disease. Although,
a lot of causeswere identiﬁed in the occurrence of coronary artery disease (CAD), there is
not any consensus about the role of these causes on the progression of CAD. Recently,
deﬁciency or excess of the trace elements are accepted as one of the responsible
mechanisms on atherogenesis. The role of the trace elements that have pivotal role in the
many of oxidant and antioxidant enzymes, on the atherosclerotic progression has not
been fully elucidated. In the present study,we aimed to investigate the role of serum trace
element levels on the atherosclerotic progression that documented with repeated coro-
nary angiography in patients with documented coronary artery disease.
Materıals-Methods: A total of eighty patients who had coronary angiogram before
and will performed because of stable angina pectoris were enrolled to the study. Blood
samples for the measurement of trace elements and transthoracic echocardiographyC216 JACC Vowere performed for each patient. According to second coronary angiogram, the study
population were divided in to two groups as progression or not progression. Serum
trace elements were examined between groups.
Results: There were 40 patients in progression group (61.811.1 year) and 40 patients
(60.314.6 year) in non-progression group. Demographic characteristics did not
statistically differ between groups. The elemental analysis of the the serum chromium
level, chromium level was 0.0937 mg/L  0.0325 mg/L in progression group, while
0.0797 mg/L  0.0287 in non-progression group (p¼0.045). Serum copper level was
determined as 1.074mg/L 0.374mg/L in non-progression group, while 1.287mg/L
0.369mg/L in progression group. There were statistically signiﬁcant difference between
groups (p¼0.013). With respect to serum selenium levels; in non-progression group
selenium levels were signiﬁcantly higher than in progression group (0.0438 mg/L 
0.151 mg/L vs, 0.0368 mg/L  0.0104 mg/L, p¼0.019).
Conclusıon: In the present study, we demonstrated for the ﬁrst time that there is
a relation between serum levels of trace elements and atherosclerotic progression.
Therefore, serum trace element levels can be use as a biomarker for the early detection
of atherosclerotic progression. Further studies should be planned in order to identify
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